On June 9, 2026, the National Organization for Joint Drug Procurement announced that the production line for amiodarone hydrochloride injection, a centrally procured life-saving drug produced by Shandong Beida Gaokua Huatai Pharmaceutical, has serious defects and has been ordered to suspend production.
Evidence EVIDENCE
Sources 2 · Archived 0
SourceTypeReliabilityLink
李老师不是你老师TG
2026-10-04 00:58 · 🖼 泰制药旗下一款集采药品存在严重缺陷，被暂停生产
First-hand
●●●●●
凤凰网转澎湃：又有药企被取消集采中选资格
2026-10-09 09:47 · 6月9日，国家组织药品联合采购办公室（简称“联采办”）发布公告，根据2026年6月9日山东省药监局药品生产监督检查结果通告
Web Source
●●●●●
Context CONTEXT
Cause
Not recorded yet
This event
National Drug Procurement Office Reports Serious Defects in Production Line of Centrally Procured Drug Amiodarone Hydrochloride Injection; Production Suspended
2026.06.09 · Official claim
Effect
Not recorded yet